Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Part D2 Azd2014 Combination With Azd8186

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01884285Phase 1CompletedPrimary

AZD8186 First Time In Patient Ascending Dose Study

Showing all 1 trials

Research Network

Common Treatments

  • Part D2 Azd2014 Combination With Azd81861
  • Part C1 Abiraterone Acetate Combination With Azd81861
  • Part B Azd8186 Monotherapy1
  • Part A Azd8186 Monotherapy1
  • Part C2 Abiraterone Acetate Combination With Azd81861

Active Sponsors

  • AstraZeneca1

Top Investigators

Related Conditions

  • Squamous Nonsmall Cell Lung Cancer Sqnsclc1
  • Triple Negative Breast Cancer Tnbc1

Activity Timeline